Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



High-Dose Trivalent Influenza Vaccine or Standard-Dose Quadrivalent Inactivated Influenza Vaccine in Treating Adult Stem Cell Transplant Recipients

This randomized phase II studies the side effects of high-dose trivalent influenza vaccine or standard-dose quadrivalent inactivated influenza and how well they work in treating adult patients undergoing stem cell transplant. Season influenza can cause more severe infections in patients who have had a stem cell transplant since their immune system doesn’t work as well. Influenza vaccine may provide better protection against flu in adults.
Not Available
II
Halasa, Natasha
NCT03179761
VICCBMT1733

Prospective Validation of Prostate Biomarkers for Repeat Biopsy: The PRIORITY Study

Prostate

Prostate
N/A
Chang, Sam
VICCURO1734

Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors

Multiple Cancer Types

The purpose of this study is to evaluate the safety and effectiveness of this investigational drug, brigatinib (AP261136) in patients with advanced non-small cell lung cancer Non-small cell lung cancer (NSCLC) who have had first-line treatment for their cancer and it still got worse, even after, or while taking drugs called ALK inhibitors, or anti-cancer drugs that act on tumors. Some examples of these anti-cancer drugs are: KEYTRUDA® or ALECENSA®).
Lung, Non Small Cell
II
Horn, Leora
NCT02706626
VICCTHO1736

Sapanisertib in Treating Patients with Locally Advanced or Metastatic Bladder Cancer with TSC1 and / or TSC2 Mutations

Bladder

This pilot phase II trial studies how well sapanisertib works in treating patients with bladder cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic) with tuberous sclerosis (TSC)1 and / or TSC2 mutations (changes in deoxyribonucleic acid [DNA]). Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Bladder
II
Davis, Nancy
NCT03047213
VICCURO1723

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3 / Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

Leukemia

The purpose of this study is to compare relapse-free survival between participants with FLT3 / ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem cell transplant (HCT) and are randomized to receive gilteritinib or placebo beginning after the time of engraftment for a two year period.
Leukemia
III
Byrne, Michael
NCT02997202
VICCBMT1740

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors

Multiple Cancer Types

The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors. The main purpose of the safety lead-in (dose-finding) part of the study is to determine the safety and tolerability of anetumab ravtansine in combination with cisplatin and in combination with gemcitabine, and to determine the MTD of anetumab ravtansine in combination with cisplatin for mesothelin expressing advanced cholangiocarcinoma and in combination with gemcitabine for mesothelin expressing advanced adenocarcinoma of the pancreas. Patients will receive anetumab ravtansine every three weeks in monotherapy for most indications. In cholangiocarinoma and adenocarinoma of the pancreas, 3-weekly anetumab ravtansine is administered in combination with cisplatin or gemcitabine respectively (both administered in a 2 week on / 1 week off schedule). Treatment will continue until disease progression or until another criterion for withdrawal is met. .Efficacy will be measured by evaluating the tumor's objective response rate. Radiological tumor assessments will be performed at defined time points until the patient's disease progresses. Blood samples will be collected for safety, pharmacokinetic and biomarker analysis. Archival or fresh biopsy tissue will also be collected for mesothelin expression testing and biomarker analyses.
Breast, Endocrine, Esophageal, Gastrointestinal, Lung, Non Small Cell, Pancreatic
I
Horn, Leora
NCT03102320
VICCPHI1742

Tumor-Treating Fields Therapy in Preventing Brain Tumors in Patients with Extensive-Stage Small Cell Lung Cancer

Multiple Cancer Types

This trial studies how well tumor-treating fields therapy works in preventing brain tumors in patients with small cell lung cancer that has spread to other places in the body. Tumor-treating fields therapy involves the use of the NovoTTF-200A which delivers alternating electrical fields, or tumor treating fields, through ceramic discs placed on the head. This electric force may slow and / or reverse tumor growth by disrupting the way cancer cells grow.
Lung, Small Cell
N/A
Attia, Albert
NCT03607682
VICCTHO1747

M3541 in Combination With Radiotherapy in Subjects With Solid Tumors

Multiple Cancer Types

This dose-escalation study will evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and explore antitumor activity of M3541 in combination with fractionated palliative radiotherapy (RT) in subjects with solid tumors with malignant lesions in the thorax, abdominal cavity, head and neck region, or extremities likely to benefit from palliative RT.
Esophageal, Gastric/Gastroesophageal, Gastrointestinal, Head/Neck, Lung, Miscellaneous, Phase I
I
Not Available
NCT03225105
VICCPHI1748

Standard Chemotherapy in Treating Young Patients with Medulloblastoma or Other Central Nervous System Primitive Neuro-ectodermal Tumors

Neuroblastoma (Pediatrics)

This phase IV trial studies how well standard chemotherapy works in treating young patients with medulloblastoma or other central nervous system primitive neuro-ectodermal tumors. Drugs used in standard chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Neuroblastoma (Pediatrics)
IV
Esbenshade, Adam
NCT02875314
VICCPED1751

Derazantinib in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Liver

This pivotal, open-label, single-arm study will evaluate the anti-cancer activity of derazantinib by Objective Response Rate (ORR) by central radiology review as per RECIST v1.1 in subjects with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) whose tumors harbor FGFR2 gene fusions (by FISH performed by the central laboratory) and who received at least one prior regimen of systemic therapy. Subjects will be dosed orally once per day at 300 mg of derazantinib capsules.
Liver
II
Goff, Laura
NCT03230318
VICCGI1754

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: